Familial Hypercholesterolemia: Genetics, Symptoms, Diagnosis and Treatment - A Literature Overview by Maciej Rutkiewicz, Sabina Przygodzka, Katarzyna Gadżała, Karolina Garbino, Katarzyna Brudniak, Antoni Szuścik, Magdalena Czyczerska

Subjects: Get full text

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma by Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, Maria Sofia Semprini, Chiara Cappello, Stefania Angelicola, Arianna Palladini, Patrizia Nanni, Louise Goksøyr, Cyrielle Fougeroux, Manuel L. Penichet, Adam Frederik Sander, Pier-Luigi Lollini

Subjects: Get full text

Causal relationship of familial hypercholesterolemia with risk of intestinal vascular disorders: A mendelian randomization study by Gang Wei, Cheng Zhang, Feng-Jie Shen, Hua-Qi Guo, Lin Liu

Subjects: Get full text

Optimal calorie restriction threshold: effect of FATmax exercise combined with different proportions of calorie restriction on hypercholesterolemia by Yuetong Wu, Li Zhang, Jing Li, Boyang Xue, Wenyuan Shang, Yingli Lu

Subjects: “…proprotein convertase subtilisin kexin type 9 (PCSK9)…”
Get full text

Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review by Fang Jia, Shun-Yi Shi, Si-Fan Fei, Min Zhou, Jian-Jun Li

Subjects: “…proprotein convertase subtilisin/kexin type 9 inhibitors (pcsk9i)…”
Get full text

Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases by Nicola Ferri

“…This paper summarizes the current knowledge of the basic molecular mechanism underlying the regulatory effect of LDLR expression by PCSK9 obtained from in vitro cell-cultured studies and the analysis of the crystal structure of PCSK9. …”
Get full text

Associations between lipid-lowering drugs and urate and gout outcomes: a Mendelian randomization study by Min Liu, Na Yin, Yuhang Zhu, Aili Du, Chunyuan Cai, Pengyuan Leng

“…The study’s exposures encompassed genetic variants within drug target genes (HMGCR, PCSK9, NPC1L1), each representing distinct lipid-lowering mechanisms. …”
Get full text

Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study by Haifeng Yu, Xiaofei Zhang, Bian Wen, Shuo Hu, Bin Ni

“…CONCLUSIONS In conclusion, this study reveals inconsistent associations between genetic proxy inhibition of APOB, CETP, HMGCR, NPCIL, PCSK9 and LDLR with LRD in specific populations.…”
Get full text

The impact of a humanized bile acid composition on atherosclerosis development in hypercholesterolaemic Cyp2c70 knockout mice by Tess Yntema, Tim R. Eijgenraam, Niels J. Kloosterhuis, Rick Havinga, Mirjam H. Koster, Milaine V. Hovingh, Jan Freark de Boer, Debby P. Y. Koonen, Folkert Kuipers

“…To conclude, a human-like BA composition ameliorated PCSK9-GOF-induced hypercholesterolaemia in WD-fed mice which translated into a tendency towards smaller atherosclerotic lesions.…”
Get full text

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis by Jeff Clarke, Xiaofei Wang, Thomas Stinchcombe, Scott J Antonia, Jeffrey Crawford, Neal Ready, Konstantin H Dragnev, Lin Gu, Cameron Wood, James M Isaacs, Liliana Lyniv, Kent Weinhold, Jacob M Kaufman, Eziafa I Oduah, Betty C Tong, Dennis Wigle

“…Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased across our patient cohort over time from baseline until postsurgery and remained elevated at the end of treatment. …”
Get full text

Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement by Gary J. Martin, Meron Teklu, Edwin Mandieka, Joe Feinglass

“…At follow-up, 87.8% of patients were prescribed a statin, 9.7% were on ezetimibe, and 0.5% were on a PCSK9 inhibitor. Mean LDL-C at follow-up was 75.6 mg/dL and 45.5% of patients were on high-intensity treatment. …”
Get full text

Potential and mechanisms of indigenous Indonesian medicinal plants in treating sexual dysfunction: A systematic review and pharmacological network overview by Sukardiman, Roihatul Mutiah, Rosita Handayani

“…The pharmacology network analysis demonstrated that the compounds present in Eurycoma longifolia, specifically stigmasterol, eurycomanone, and eurycomalactone, target 13 genes associated with erectile dysfunction (ED), which include BCL2, AKT1, SOAT1, PCSK9, ACHE, BDNF-AS, TMX2-CTNND1, GSK3B, LINCO1672, TP53, H19, HIF1A, and IL1B. …”
Get full text

Combining In Vitro, In Vivo, and In Silico Approaches to Explore the Effect of <i>Ceratonia siliqua</i> and <i>Ocimum basilicum</i> Rich Phenolic Formula on Lipid Metabolism and Pl... by Mohammadine Moumou, Amani Tayebi, Abderrahmane Hadini, Omar M. Noman, Abdulsalam Alhalmi, Hamza Ahmoda, Souliman Amrani, Hicham Harnafi

“…This includes the HMG-CoA reductase, PPARα/γ, PCSK9, Cyp7a1, and ATP-citrate lyase. Conclusions: The CBF could be a good source of natural supplements, functional foods, and pharmaceuticals effective in managing hyperlipidemia and oxidative stress and preventing their related cardiovascular disorders.…”
Get full text

Searching for new genes associated with the familial hypercholesterolemia phenotype using whole-genome sequencing and machine learning by D. E. Ivanoshchuk, A. B. Kolker, O. V. Timoshchenko, S. E. Semaev, E. V. Shakhtshneider

“…Rare pathogenic variants in the LDLR gene are present in 75–85 % of cases with an identified molecular genetic cause of the disease, and variants in other genes (APOB, PCSK9, LDLRAP1, ABCG5, ABCG8, and others) occur at a frequency of &lt; 5 % in this group of patients. …”
Get full text

Clonal hematopoiesis of indeterminate potential and type 2 diabetes mellitus among patients with STEMI: from a prospective cohort study combing bidirectional Mendelian randomizatio... by Xiaoxiao Zhao, Jiannan Li, Shaodi Yan, Yu Tan, Runzhen Chen, Nan Li, Jinying Zhou, Chen Liu, Peng Zhou, Yi Chen, Hongbing Yan, Hanjun Zhao, Li Song

“…(iv) The correlation between PCSK9 and the Tet2-CHIP mutation was observed in both the T2DM cohort (correlation = 0.1215, P = 0.011) and the overall enrolled cohort (correlation = 0.0578, P = 0.0382). …”
Get full text